Neuropath Therapeutics in Wuhan, China has announced a Series A investment of €16.9M for the development of Leber’s Hereditary Optic Neuropathy (LHON)
Neuropath Therapeutics, a start-up company based in Wuhan Optics Valley Biological City, China, has announced a Series A funding round on April 8th for €16.9M… Read More »Neuropath Therapeutics in Wuhan, China has announced a Series A investment of €16.9M for the development of Leber’s Hereditary Optic Neuropathy (LHON)